Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19

Tony Y Zhang; Boyu Zhong

doi:10.1016/j.medidd.2020.100036

Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19

Med Drug Discov. 2020 Mar:5:100036. doi: 10.1016/j.medidd.2020.100036. Epub 2020 Apr 9.

Authors

Tony Y Zhang¹, Boyu Zhong¹

Affiliation

¹ Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.

Abstract

This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the potential surge in demand.

Publication types

Review